Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zealand Pharma A/S ADR (ZEAL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 551,040
  • Shares Outstanding, K 30,750
  • Annual Sales, $ 21,230 K
  • Annual Income, $ -41,360 K
  • 36-Month Beta N/A
  • Price/Sales 26.47
  • Price/Cash Flow N/A
  • Price/Book 11.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.51
  • Number of Estimates 1
  • High Estimate -0.51
  • Low Estimate -0.51
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -121.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.10 +25.53%
on 08/22/18
18.91 -6.40%
on 09/18/18
+3.70 (+26.43%)
since 08/21/18
3-Month
12.01 +47.38%
on 07/03/18
18.91 -6.40%
on 09/18/18
+3.18 (+21.90%)
since 06/21/18
52-Week
12.01 +47.38%
on 07/03/18
19.36 -8.57%
on 10/12/17
-0.81 (-4.38%)
since 09/21/17

Most Recent Stories

More News
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants

Company announcement - No. 22 / 2018

ZEAL : 17.70 (-1.23%)
Blog Exposure - Zealand's End-of-Phase-2 Meeting with FDA Confirmed the Path Forward for Phase-3 Program of Glepaglutide for Short Bowel Syndrome

Stock Monitor: Cytokinetics Post Earnings Reporting

ZEAL : 17.70 (-1.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ZEAL with:

Business Summary

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.

See More

Key Turning Points

2nd Resistance Point 18.34
1st Resistance Point 18.13
Last Price 17.70
1st Support Level 17.67
2nd Support Level 17.42

See More

52-Week High 19.36
Last Price 17.70
Fibonacci 61.8% 16.55
Fibonacci 50% 15.69
Fibonacci 38.2% 14.82
52-Week Low 12.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar